Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming

December 04, 2019 8:30 AM EST
Piper Jaffray 31st Annual Healthcare Conference

Prior

November 12, 2019 8:35 AM MST
Credit Suisse 28th Annual Healthcare Conference

October 29, 2019 8:00 AM EDT
Q3 2019 Incyte Corporation Earnings Conference Call

September 27, 2019 11:00 AM EDT
ESMO 2019: Pemigatinib Development Update

SEC Filings

Filing date Description Filing Group View

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

CT ORDER

Other

Investor Contacts

Michael Booth D.Phil
Divisional VP of Investor Relations and Corporate Social Responsibility
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Ayala
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: layala@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536